Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Novel Flow Cytometric Antibody Panel and Dedicated Analysis Algorithm for Automated Fully Standardized Minimal Residual Disease Detection in Chronic Lymphocytic Leukemia.
Am J Hematol
January 2025
Clinic III (Hematology, Oncology and Palliative Medicine), Special Hematology Laboratory, Rostock University Medical School, Rostock, Germany.
Comparative image quality and dosimetric performance of two generations of dedicated breast CT systems.
Med Phys
January 2025
Department of Medical Imaging, Radboud University Medical Center, Nijmegen, The Netherlands.
Background: Dedicated breast computed tomography (bCT) systems offer detailed imaging for breast cancer diagnosis and treatment. As new bCT generations are developed, it is important to evaluate their imaging performance and dose efficiency to understand differences over previous models.
Purpose: To characterize the imaging performance and dose efficiency of a second-generation (GEN2) bCT system and compare them to those of a first-generation (GEN1) system.
Public Involvement to Enhance Care Home Research; Collaboration on a Minimum Data Set for Care Homes.
Health Expect
February 2025
Centre for Research in Public Health and Community Care (CRIPACC), University of Hertfordshire, Hatfield, UK.
Introduction: Information on care home residents in England is captured in numerous data sets (care home records, General Practitioner records, community nursing, etc.) but little of this information is currently analysed in a way that is useful for care providers, current or future residents and families or that realises the potential of data to enhance care provision. The DACHA study aimed to develop and test a minimum data set (MDS) which would bring together data that is useful to support and improve care and facilitate research.
View Article and Find Full Text PDFNeo-adjuvant FOLFOX with and without panitumumab for patients with KRAS-wt locally advanced colon cancer: results following an extended biomarker panel on the FOxTROT Trial embedded phase II population.
Ann Oncol
January 2025
Division of Pathology & Data Analytics, Leeds Institute of Medical Research, University of Leeds, UK.
Background: The FOxTROT trial has reported advantages of neoadjuvant chemotherapy (NAC) in locally advanced colon cancer (LACC). Here we present results of the embedded randomized phase II trial testing the addition of panitumumab to neoadjuvant FOLFOX compared with FOLFOX alone in RAS and BRAF-wild-type patients and with biomarker hyperselction.
Patients And Methods: Patients had operable, CT-predicted stage T3-4, N0-2, M0 colon adenocarcinoma.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!